ETH-155036

N/A

Report date: 2023/11/14 11:47:53

NME

Base Information

Drug NameETH-155036

Drug Alias NameETH-155036ETH155036

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsCyclin-dependent kinase 6 inhibitorsColony stimulating factor 1 receptor modulators

TargetsTyrosine-protein kinase receptor FLT3Cyclin-dependent kinase 6Colony stimulating factor 1 receptor

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesShengke Pharmaceutical (Jiangsu) Co Ltd

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShengke Pharmaceutical (Jiangsu) Co Ltd

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A